Citigroup Inc Karuna Therapeutics, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$161.01 - $317.85 $16.9 Million - $33.3 Million	104,913 Added 284.9%	141,738 $44.9 Million
Q3 2023 Nov 09, 2023	BUY	$164.66 - $218.08 $2.89 Million - $3.82 Million	17,537 Added 90.92%	36,825 $6.23 Million
Q2 2023 Aug 10, 2023	SELL	$176.32 - $240.22 $2.49 Million - $3.39 Million	-14,120 Reduced 42.27%	19,288 $4.18 Million
Q1 2023 May 11, 2023	BUY	$161.33 - $204.36 $2.22 Million - $2.81 Million	13,750 Added 69.95%	33,408 $6.07 Million
Q4 2022 Feb 09, 2023	SELL	$191.53 - $236.82 $1.44 Million - $1.78 Million	-7,505 Reduced 27.63%	19,658 $3.86 Million

Q3 2022 Nov 10, 2022	SELL	$123.79 - $277.42 $1.61 Million - $3.6 Million	-12,986 Reduced 32.34%	27,163 $6.11 Million
Q2 2022 Aug 10, 2022	BUY	$93.97 - $143.33 $2.8 Million - $4.28 Million	29,839 Added 289.42%	40,149 $5.08 Million
Q1 2022 May 12, 2022	SELL	$98.9 - $132.37 $6.09 Million - $8.15 Million	-61,573 Reduced 85.66%	10,310 $1.31 Million
Q4 2021 Feb 10, 2022	BUY	$110.64 - $159.4 $5.49 Million - $7.91 Million	49,615 Added 222.81%	71,883 $9.42 Million
Q3 2021 Nov 10, 2021	BUY	$101.2 - $125.87 $2.25 Million - $2.8 Million	22,268 New	22,268 $2.72 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.